Tenvie Therapeutics Inc. has divulged NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord injury, multiple sclerosis, Niemann-Pick ...

A brain-penetrant SARM1 inhibitor, NB-4746 has demonstrated potential in preventing axon degeneration and offering neuroprotection in preclinical models of nerve injury and disease. The Phase I ...

Disarm has discovered novel, potent SARM1 inhibitors and is advancing them into preclinical development for diseases including peripheral neuropathy as well as ALS and MS. Axonal degeneration is a ...